A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using \([^{18}F]\)MK-6240

Guilherme D. Kolinger¹, David Vállez García¹, Talakad G. Lohith², Eric D. Hostetler², Cyrille Sur², Arie Struyk³, Ronald Boellaard¹,⁴† and Michel Koole⁵*†

Abstract

Background: \([^{18}F]\)MK-6240 is a PET tracer with sub-nanomolar affinity for neurofibrillary tangles. Therefore, tau quantification is possible with \([^{18}F]\)MK-6240 PET/CT scans, and it can be used for assessment of Alzheimer’s disease. However, long acquisition scans are required to provide fully quantitative estimates of pharmacokinetic parameters. Therefore, on the present study, dual-time-window (DTW) acquisitions was simulated to reduce PET/CT acquisition time, while taking into consideration perfusion changes and possible scanning protocol non-compliance. To that end, time activity curves (TACs) representing a 120-min acquisition (TAC120) were simulated using a two-tissue compartment model with metabolite corrected arterial input function from 90-min dynamic \([^{18}F]\)MK-6240 PET scans of three healthy control subjects and five subjects with mild cognitive impairment or Alzheimer’s disease. Therefore, TACs corresponding to different levels of specific binding were generated and then various perfusion changes were simulated. Next, DTW acquisitions were simulated consisting of an acquisition starting at tracer injection, a break and a second acquisition starting at 90 min post-injection. Finally, non-compliance with the PET/CT scanning protocol were simulated to assess its impact on quantification. All TACs were quantified using reference Logan’s distribution volume ratio (DVR) and standardized uptake value ratio (SUVR90) using the cerebellar cortex as reference region.

Results: It was found that DVR from a DTW protocol with a 60-min break between two 30-min dynamic scans closely approximates the DVR from the uninterrupted TAC120, with a regional bias smaller than 2.5%. Moreover, SUVR90 estimates were more susceptible (regional bias \(\leq 19\%\)) to changes in perfusion compared to DVR from a DTW TAC (regional bias \(\leq 10\%\)). Similarly, SUVR90 was affected by late-time scanning protocol delays reaching an increase of 8% for a 20-min delay, while DVR was not affected (regional bias < 1.5%) by DTW protocol non-compliance.

Conclusions: Therefore, such DTW protocol has the potential to increase patient comfort and throughput without compromising quantitative accuracy and is more reliable against SUVR in terms of perfusion changes and protocol deviations, which could prove beneficial for drug effect assessment and patient follow-up using longitudinal \([^{18}F]\) MK-6240 PET imaging.

Keywords: \([^{18}F]\)MK-6240, Dual-time-window, PET quantification, Reference logan, Tau imaging

Background

Accumulation of neurofibrillary tangles (NFT) is related to cognitive decline and is one of the neuropathological hallmarks of Alzheimer’s disease (AD) [1]. Furthermore, AD progression has been shown to follow a specific pattern described by the Braak Stages [2] such...
that \emph{in-vivo} quantification of NFTs may support disease staging and assessing the neurological condition of patients. This can be achieved with positron emission tomography (PET) tracers that bind to hyper-phosphorylated tau proteins, such as \textsuperscript{18}F\textsuperscript{MK}-6240 which has sub-nanomolar affinity for NFTs and has been studied and validated recently in healthy control (HC), mild cognitive impairment (MCI), and AD subjects [3–7].

Previous in-human \textsuperscript{18}F\textsuperscript{MK}-6240 studies performed dynamic PET scans with a duration up to 180 min and used a reference tissue model with the cerebellum as reference brain region. This reference tissue model approach uses the time activity curve (TAC) of a reference tissue assumed to be devoid of specific tracer binding to estimate the ratio of specific to non-displaceable binding in target regions. This way, arterial cannulation for blood collection during the PET scan is obviated, avoiding an invasive and uncomfortable procedure, which often is not feasible in ill-conditioned patients. However, the long PET scanning times increases patient discomfort and the risk of head motion, which could hamper accurate quantification, and long scanning times are impractical for clinical routine scheduling. To address the issues of long dynamic PET scanning, one could consider standardized uptake value ratio (SUVR) relative to the cerebellum of a late static PET scan to estimate specific \textsuperscript{18}F\textsuperscript{MK}-6240 binding. A previous study [4] proposed static scanning at 90 min post-injection (p.i.), while another study [5] found that SUVR was still increasing at 135 min p.i. in subjects with high \textsuperscript{18}F\textsuperscript{MK}-6240 binding. In addition to the uncertainty about the optimal time-window for static \textsuperscript{18}F\textsuperscript{MK}-6240 scanning, SUVR can be susceptible to blood–brain barrier (BBB) functionality changes and variations in cerebral blood flow (CBF). It has been shown that such changes can introduce a bias to SUVR-based longitudinal assessment of deposition of \beta-amyloid plaques [8–10], another AD neuropathological hallmark. It can also be expected that drug intervention may have effects on perfusion. Given the high BBB permeability and fast plasma clearance of \textsuperscript{18}F\textsuperscript{MK}-6240 [6, 11, 12], one can also expect the influence of those factors and regional CBF functionalities to affect tau quantification. Thus, SUVR-based quantification should be considered carefully, notably in longitudinal settings for cases where the vascular component is expected to play an important role, such as for stroke patients or patients with cognitive decline. Furthermore, tau pathology and changes in relative CBF have been observed to independently contribute to cognitive deficits in AD [13], emphasizing the need to understand the interplay between tau load, tracer binding, and longitudinal changes in CBF.

Nevertheless, SUVR from \textsuperscript{18}F\textsuperscript{MK}-6240 has potential for stratification of different stages of tau accumulation in a cross-sectional setting [7].

To avoid the limitations of SUVR quantification, two studies implemented a dual-time-window (DTW) protocol consisting of first dynamic PET scan starting at tracer injection, followed by a short resting period of 15 min [5] or 30 min [6], and a second dynamic PET scan starting after the short break. However, these studies did not evaluate the potential impact of a DTW protocol on the PET quantification nor did they optimize the scan and break duration of their DTW protocol. For amyloid quantification, there has been an evaluation of the effects of a DTW quantification and changes [14, 15]; however, no such exploration has been done for tau tracers.

The aim of the present study was to develop and evaluate a DTW protocol for accurate \textsuperscript{18}F\textsuperscript{MK}-6240 PET quantification that is comfortable for patients, suitable for longitudinal studies and drug intervention assessment, and appropriate for clinical routine. For this purpose, DTW protocols combining a first dynamic PET scan of variable length, starting at tracer injection, with a second 90- to 120-min PET scan were compared to an uninterrupted 120-min dynamic PET scan using a Logan reference tissue model (Ref Logan) with grey matter cerebellum as reference region. Furthermore, changes in perfusion were simulated to assess the impact of CBF and BBB permeability variations on Ref Logan and SUVR quantification, where SUVR was calculated relative to the grey matter cerebellum for the 90- to 120-min PET scan. Finally, small delays for the 90- to 120-min PET scan were simulated to evaluate the quantitative impact of possible non-compliance with the clinical routine protocol.

\textbf{Methods}

\textbf{Subjects and image acquisition}

PET and MR data of eight subjects were used for this study, three healthy controls (HC) and five patients classified with either Mild-Cognitive Impairment or Alzheimer’s Disease (MCI/AD). HC subjects had a Mini-Mental State Examination (MMSE) score of at least 27 and presented no cognitive complaints, MCI subjects had an MMSE score of at least 26 while presenting episodic memory impairment and a positive amyloid PET examination, and AD subjects had an MMSE score lower than 28 and were clinically diagnosed as probable AD based on the National Institute of Neurologic and Communicative Disorders and Stroke and of the Alzheimer Disease and Related Disorders Association criteria. Subject demographics are given in Table 1. The study was conducted at the University Hospital Leuven, Belgium, and approved by the local Ethics Committee (University Hospitals Leuven/
The subjects (or legal representative) gave written informed consent before enrollment in the study.

Dynamic 90-min PET/computed tomography (CT) scans were acquired in 3D list mode on a HiRez Biograph 16 PET/CT camera (Siemens Medical Solutions) after intravenous bolus injection of $^{[18F]}$MK-6240 (159 ± 3.3 MBq). A low-dose CT was acquired at the beginning of the PET/CT scan for attenuation correction. The dynamic acquisitions consisted of 31 frames ($6 \times 10$, $6 \times 20$, $2 \times 30$, $2 \times 60$, $2 \times 120$, $10 \times 300$ and $3 \times 600$ s) and were reconstructed with a 3D filtered backprojection algorithm including correction for scatter, attenuation, decay, random coincidences, and dead time. A Gaussian post-reconstruction filter of 5 mm was applied, and the images had a final voxel size of $2.14 \times 2.14 \times 2.0$ mm$^3$ with a matrix size of $128 \times 128 \times 82$. All subjects underwent a structural high-resolution T1-weighted MRI scan on a 3 T MR scanner (Philips Healthcare).

Manual arterial blood sampling was acquired for three HC and three MCI/AD subjects at 10 s intervals for the first 100 s of the PET/CT scan and approximately 2, 2.5, 3.5, 15, 30, 45, 60, 75, and 90 p.i.. These arterial blood samples were used to determine radioactivity levels in whole-blood and fractions of intact tracer in plasma as a function of time, such that a metabolite corrected arterial input function (AIF) was obtained for six subjects. Parent fractions for S2 had $\gamma$-counter measurement errors, therefore a HC-population-average parent fraction was used for this subject. Arterial cannulation failed two MCI/AD subjects (S7 and S8), and an AD-population-average arterial input function was used based on the average AIF of the three MCI/AD subjects with a measured AIF. Further details on the subject recruitment, radiotracer synthesis, PET/CT and MRI acquisitions, measurement of radiotracer in plasma, and parent fractions can be found elsewhere [6].

### Table 1: Subject demographics

| Subject | Clinical diagnosis | Sex | Age (y) | MMSE score | Dose (MBq) | Arterial sampling |
|---------|-------------------|-----|---------|------------|------------|------------------|
| S1      | HC                | F   | 59      | 29         | 161        | Yes              |
| S2      | HC                | M   | 66      | 29         | 153        | Yes              |
| S3      | HC                | M   | 68      | 29         | 155        | Yes              |
| S4      | AD                | M   | 67      | 11         | 160        | Yes              |
| S5      | MCI               | M   | 74      | 28         | 162        | Yes              |
| S6      | MCI               | M   | 80      | 27         | 158        | Yes              |
| S7      | AD                | M   | 74      | 13         | 163        | No               |
| S8      | AD                | F   | 70      | 13         | 157        | No               |

Using PMOD (version 4.0, PMOD Technologies LLC), motion correction was performed on the 90-min dynamic PET data by aligning all frames with the average PET signal of the first five minutes of the dynamic PET scan using a normalized mutual information algorithm to determine the optimal rigid transformation. Next, PET data were co-registered with the corresponding T1w MRI data by a rigid transformation, obtained by maximizing the normalized mutual information between the average PET signal of all frames with the MRI data. Tissue class probability maps for grey matter (GM), white matter (WM), and cerebrospinal fluid (CSF) were estimated from each subject’s T1w MRI using the Computational Anatomy Toolbox (CAT) 12 (Jena University Hospital, Department of Psychiatry and Neurology[16]), a toolbox extension for Statistical Parametric Mapping (SPM) version 12 (Wellcome Centre for Human Neuroimaging). Next, each subject’s T1w MRI was spatially normalized to Montreal Neurological Institute (MNI) space using the Unified Segmentation Method, a non-linear registration approach regularized by the subject’s tissue probability maps [17, 18].

Anatomical brain regions of interest were initially defined based on the Hammers’ atlas [19]. Next, these predefined brain regions were combined to create composite anatomical volumes of interest (VOI) that are related to the Braak stages of disease progression:

- **VOI 1:** Entorhinal cortex (related to Braak stage 1)
- **VOI 2:** Hippocampus (related to Braak stage 2)
- **VOI 3:** Fusiform Gyrus + Amygdala (related to early Braak stage 3)
- **VOI 3+:** Medial part of the Anterior Temporal Lobe (related to advanced Braak stage 3)
- **VOI 4:** Lateral part of the Anterior Temporal Lobe + Medial and inferior temporal gyrus (related to Braak stage 4)
• VOI 5: All other brain regions except precentral and postcentral gyrus (related to Braak stage 5)
• VOI 6: Precentral and postcentral gyrus (related to Braak stage 6)

The cerebellum VOI from the Hammers’ atlas was masked with the grey matter tissue map (at 30% probability) to create the reference region.

Data analysis was carried in the MRI space of each subject, therefore the PET images were co-registered with their respective MRI. Furthermore, the predefined VOIs in MNI space were spatially transformed to the MRI subject space by the inverse nonlinear transformation used for the spatial normalization. The VOIs in MRI subject space were limited to grey matter by applying a threshold of 30% to the GM tissue probability map and were then projected on the 90-min dynamic PET data to extract the regional TACs.

Dynamic PET simulations and quantification
Kinetic parameters
A three exponential function was fitted to the whole blood and plasma activity curves, while a Hill function was fitted to metabolite data. Next, a reversible two-tissue compartmental model (2TCM) was fitted to the regional TACs using the blood activity concentrations and metabolite corrected activity concentrations in arterial plasma as input function [6]. The blood volume was fixed to 5%, data points were weighted based on frame duration and the decay at frame mid-time relative to tracer injection, and the tissue TACs were corrected for blood delay. Based on the 2TCM kinetic parameters, TACs were extrapolated to 120 min length (TAC120). Distribution volume ratio (DVR) was obtained as the target-to-reference ratio of the total distribution volume (VT) from each tissue. Following, changes in perfusion were simulated by altering the K1 (tracer influx rate from plasma to tissue) and k2 (tracer clearance rate from tissue to plasma) parameters from the 2TCM model using the grey matter cerebellum as the reference region.

Quantitative and statistical analysis
All simulated TACs were analyzed with the Ref Logan model using the grey matter cerebellum as the reference region, assuming independence of the reference tissue clearance rate which requires a late equilibrium time, and therefore t* was fixed at 90 min. Furthermore, SUVR was calculated for each TAC using the 90–120 min interval p.i. (SUVR90), corresponding to Part 2 of the DTW protocol, as the average uptake in the target region relative to the average uptake in the cerebellar cortex. Impact of a delayed late time scan was evaluated for both Ref Logan and SUVR.

Inferential statistical analysis was performed to explore how changes to TAC120 (either changing perfusion, introducing a break, perfusion changes in a DTW acquisition, and considering scanning protocol non-compliance), affected Ref Logan DVR and SUVR. For that matter, the generalized estimating equations (GEE) model was used as it is known to achieve higher statistical power with small sample sizes than ANOVA and does not require data normality [20–22]. On the present study, the GEE model was built with a linear-scale response and an independent working correlation matrix. To compare DVR and SUVR (the dependent variables) of TACs with changed perfusion against themselves of TAC120 with fitted K1 and k2, models using the full interaction of diagnosis, region, and K1 change as predictor factor (independent variables) were applied to the data.
Meanwhile, for the assessment of the impact of the DTW break length in DVR estimation, a model using the full interaction of diagnosis, region, and break was fitted, and, finally, to study the impact of protocol non-compliance on DVR and SUVR, models with the full interaction between diagnosis, region, and delay were fitted to the data. All models were applied independently to the dependent variables: Ref Logan DVR and SUVR. The results of these models were reported with the relative percentage change alongside its 95% confidence interval, and a p value of 0.05 was used as the threshold for considering statistical significance (Wald method, without correction for multiple pairwise comparisons). Complete results of the GEE models were reported in the supplementary material. GEE analysis was carried out with R (version 3.6.3, Rstudio version 1.2.5033) using the packages geepack (version 1.3-1) and emmeans (version 1.4.7).

**Results**

### Simulations of 120-min TAC

The average and standard deviation for the 2TCM parameters of TAC$_{120}$ are given in Table 2.

Two-tissue compartment model kinetic parameters for TAC$_{120}$. Blood volume fraction was fixed at 5%. $K_1$ represents the tracer influx from plasma to tissue, $k_2$ the washout constant (tracer efflux from tissue to plasma), $k_3$ is the transfer from the non-displaceable to specific compartment, $k_4$ is the transfer from specific to non-displaceable compartment, DVR is the distribution volume ratio, and $V_T$ is the total distribution volume. Alternatively, $k_3$ and $k_4$ can represent interactions between the free and the non-specific binding compartments for HC subjects. This interpretation is mathematically indistinguishable from the previously described $k_3$ and $k_4$. Average and standard deviation (SD) are shown for each parameter.

### Tracer perfusion changes

The DVR from TACs with perfusion changes and constant $R_1$ showed, for HC subjects, an overall average bias (i.e., pooling target VOIs together) ranging from $-0.04\%$ to $-0.07\%$ ($p=0.789$) with $K_1+50\%$ to $-0.16\%:0.02\%$ ($p=0.137$) with $K_1+50\%$ when compared against the Ref Logan DVR of TAC$_{120}$ with the fitted $K_1$. Meanwhile, for MCI/AD subjects this bias ranged from $-0.7%$ to $-17.1\%:1.5\%$ ($p=0.007$) with $K_1-50\%$ to $1.6\%:0.9\%:5.3\%$ ($p=0.019$) with $K_1+50\%$ (Additional file 2: Table S1). The largest regional bias for perfusion changes with constant $R_1$ for HC subjects was $-1.2\%$ to $-1.9\%:0.5\%$ ($p<0.001$) on VOI 3+, while for MCI/AD subjects it was $-10.5\%:20.3\%:0.7\%$ ($p=0.035$) on VOI 4, in either case with $K_1-50\%$ (Fig. 1a and Additional file 2: Table S2).

For perfusion changes with variable $R_1$, the overall DVR bias for HC subjects ranged from $-1.2\%$ to $-1.5\%:1.0\%$.

### Table 2 Average kinetic parameters from the two-tissue compartment model

| Diagnosis   | Region    | Mean $K_1$ (SD) | Mean $k_2$ (SD) | Mean $k_3$ (SD) | Mean $k_4$ (SD) | Mean DVR (SD) | Mean $V_T$ (SD) |
|-------------|-----------|-----------------|-----------------|-----------------|-----------------|---------------|----------------|
| HC          | Cerebellum| 0.402 (0.07)    | 0.151 (0.01)    | 0.0107 (0.002)  | 0.0160 (0.005)  | 4.63 (1.5)    | 3.85 (0.9)     |
|             | VOI 1     | 0.273 (0.04)    | 0.136 (0.01)    | 0.0173 (0.003)  | 0.0200 (0.007)  | 3.85 (0.9)    | 3.80 (0.7)     |
|             | VOI 2     | 0.301 (0.06)    | 0.124 (0.01)    | 0.0148 (0.003)  | 0.0264 (0.006)  | 4.11 (0.7)    | 4.30 (1.1)     |
|             | VOI 3     | 0.283 (0.04)    | 0.125 (0.004)   | 0.0138 (0.002)  | 0.0189 (0.006)  | 4.01 (0.9)    | 4.10 (1.0)     |
|             | VOI 3+    | 0.255 (0.04)    | 0.124 (0.003)   | 0.0155 (0.003)  | 0.0157 (0.002)  | 4.11 (0.7)    | 4.30 (1.1)     |
|             | VOI 4     | 0.325 (0.05)    | 0.140 (0.01)    | 0.0139 (0.002)  | 0.0172 (0.005)  | 3.82 (0.9)    | 3.80 (0.7)     |
|             | VOI 5     | 0.362 (0.05)    | 0.160 (0.01)    | 0.0155 (0.002)  | 0.0198 (0.004)  | 4.10 (1.0)    | 4.10 (1.0)     |
|             | VOI 6     | 0.345 (0.05)    | 0.165 (0.01)    | 0.0168 (0.001)  | 0.0208 (0.004)  | 3.82 (0.9)    | 3.80 (0.7)     |
| MCI/AD      | Cerebellum| 0.408 (0.09)    | 0.140 (0.01)    | 0.0198 (0.002)  | 0.0264 (0.007)  | 4.63 (1.5)    | 5.20 (1.0)     |
|             | VOI 1     | 0.243 (0.03)    | 0.102 (0.02)    | 0.0380 (0.006)  | 0.0380 (0.006)  | 4.10 (1.0)    | 4.30 (1.1)     |
|             | VOI 2     | 0.256 (0.04)    | 0.105 (0.02)    | 0.0343 (0.007)  | 0.0203 (0.008)  | 4.10 (1.0)    | 4.30 (1.1)     |
|             | VOI 3     | 0.240 (0.05)    | 0.089 (0.02)    | 0.0363 (0.010)  | 0.0142 (0.004)  | 4.10 (1.0)    | 4.30 (1.1)     |
|             | VOI 3+    | 0.223 (0.05)    | 0.089 (0.02)    | 0.0349 (0.007)  | 0.0157 (0.004)  | 4.10 (1.0)    | 4.30 (1.1)     |
|             | VOI 4     | 0.292 (0.09)    | 0.104 (0.03)    | 0.0353 (0.014)  | 0.0166 (0.005)  | 4.10 (1.0)    | 4.30 (1.1)     |
|             | VOI 5     | 0.329 (0.07)    | 0.140 (0.02)    | 0.0326 (0.009)  | 0.0208 (0.008)  | 4.10 (1.0)    | 4.30 (1.1)     |
|             | VOI 6     | 0.338 (0.06)    | 0.162 (0.02)    | 0.0321 (0.008)  | 0.0230 (0.010)  | 4.10 (1.0)    | 4.30 (1.1)     |
Fig. 1 Average quantification bias due to perfusion changes. Changes with constant $R_1$ are shown on the left, and with variable $R_1$ on the right. Subject diagnosis is shown by data point shape and tracer influx rate ($K_1$) changes by color. a, b show the bias for Reference Logan DVR on the uninterrupted TAC (TAC$_{120}$), c, d show the bias for Reference Logan DVR on the dual-time-window TAC with 60-min break (TAC$_{DTW60}$), and e, f show the bias for SUVR$_{90}$. 

$K_1$ changes for HC:
- $K_1 \leq 50$
- $K_1 \leq 25$
- $K_1 \leq 10$
- $K_1 + 10$
- $K_1 + 25$
- $K_1 + 50$

$K_1$ changes for MCI/AD:
- $K_1 \leq 50$
- $K_1 \leq 25$
- $K_1 \leq 10$
- $K_1 + 10$
- $K_1 + 25$
- $K_1 + 50$
(p < 0.001) with K₁-50% to 0.31% [0.22%-0.41%] (p < 0.001) with K₁ + 50%, while for MCI/AD subjects it ranged from −4.9% [−8.5%:−1.4%] (p = 0.007) with K₁-50% to 1.7% [0.32%-3.1%] (p = 0.016) with K₁ + 50% (Additional file 2: Table S3). Figure 1b and Additional file 2: Table S4 also show that the largest average regional DVR bias due to perfusion changes with relative R₁ variability was −2.0% [−2.1%:−1.8%] (p < 0.001, K₁-50%, VOI 3+) for HC subjects, while for MCI/AD subjects it was −6.4% [−12.2%:−0.6%] (p = 0.031, K₁-50%, VOI 4). Notice that the average regional bias was less than 10% for any region as long as K₁ was not changed more than 25% (either constant R₁ or relative R₁ changes), regardless of diagnosis.

**DTW protocol**

Despite introducing breaks in the TACs, the DVR average regional differences between TAC DTW and TAC 120 were less than 10%, regardless of diagnosis and duration of the break (Fig. 2). When pooling all target VOIs, the average DVR bias for HC subjects was −1.6% [−2.6%:−0.6%] (p = 0.002), −0.2% [−0.6%:0.2%] (p = 0.276), 0.03% [−0.10%:0.16%] (p = 0.663) and 0.04% [−0.0002%:0.08%] (p = 0.051) for a break length of 70 min, 60 min, 50 min and 40 min, respectively, while for MCI/AD subjects the overall average DVR bias was −6.2% [−8.97%:−3.51%] (p < 0.001) for the 70-min break, −2.1% [−3.2%:−1.0%] (p < 0.001) for the 60-min break, −0.79% [−1.2%:−0.34%] (p = 0.001) for the 50-min break and −0.31% [−0.49%:−0.13%] (p = 0.001) for the 40-min break (Additional file 2: Table S5). The longest break of 70 min (TAC DTW 70) resulted in the largest DVR underestimation for both HC and MCI/AD subjects, with a regional average bias of −2.6% [−3.0%:−0.2%] (p < 0.001, VOI 3+) and −6.9% [−9.6%:−4.3%] (p < 0.001, VOI 3+), respectively (Additional file 2: Table S6). A slightly shorter break of 60 min (TAC DTW 60) introduced a relatively low average bias (<5%) for all brain regions when compared against TAC 120, irrespective of diagnosis (Fig. 2 and Additional file 2: Table S6). Because of the low bias and the flexibility that a 60-min break provides, allowing for an interleaved scan of a secondary subject during the break of the primary subject, only this DTW protocol was considered for further analysis.

**DTW protocol with tracer perfusion changes**

Overall bias for perfusion changes on TAC DTW 60 with constant R₁ ranged from −0.9% [−1.5%:−0.4%] (p = 0.001) with K₁-50% to 0.3% [0.05%:0.45%] (p = 0.015) with K₁ + 50% for HC subjects, while for MCI/AD subjects it ranged from −7.7% [−13.0%:−2.3%] (p = 0.005) with K₁-50% to 2.7% [0.83%:4.6%] (p = 0.005) with K₁ + 50% (when compared against Ref Logan DVR from TAC 120). The largest average regional DVR bias for HC subjects with TAC DTW 60 and perfusion changes with constant R₁ was −2.2% [−3.1%:−1.01%] (p < 0.001, VOI 3+, K₁-50%) and for MCI/AD subjects it was −10.1% [−19.3%:−0.93%] (p = 0.031, VOI 4, K₁-50%), as can be seen on Fig. 1c and Additional file 2: Table S8.

For perfusion changes with variable R₁ on TAC DTW 60, the overall DVR bias for HC subjects ranged from

**Fig. 2** Average DVR bias from dual-time-window TACs when compared to the 120-min uninterrupted TAC (TAC 120). The average relative bias for each region of interest is shown on the left panel, while the right panel shows the average DVR bias as function of DVR from TAC 120. Diagnoses are indicated by data point shape and break length is indicated by color.
−0.12% [−1.4%:−0.92%] (p < 0.001) with $K_1$-50% to −0.46% [−0.57%:−0.36%] (p < 0.001) with $K_1$ + 50%, while for MCI/AD subjects it ranged from −5.3% [−9.4%:−1.2%] (p = 0.012) with $K_1$-50% to 0.99% [0.34%:1.7%] (p = 0.003) with $K_1$ + 50% (when compared against Ref Logan DVR from TAC120; Additional file 2: Table S9). For HC subjects, the largest regional average DVR bias was −0.46% [−0.57%:−0.36%] (p < 0.001) with $K_1$ + 50% (when compared against Ref Logan DVR from TAC120; Additional file 2: Table S9). For HC subjects, the largest regional average DVR bias was −2.1% [−2.4%:−1.8%] (p < 0.001, VOI 3+, $K_1$-50%), while for MCI/AD subjects it was −6.8% [−12.4%:−1.2%] (p = 0.017, VOI 3, $K_1$-50%) (Fig. 1d and Additional file 2: Table S10).

**Non-compliance with DTW protocol**

Delaying the start of Part 2 of the DTW protocol after a planned 60-min break, effectively increasing this break, only had a small impact on Ref Logan DVR estimates when compared to TAC DTW60 (Fig. 3). The overall bias for HC subjects was −0.1% [−0.19%:−0.01%] (p = 0.036), −0.1% [−0.38%:−0.002%] (p = 0.047), and −0.33% [−0.70%:0.03%] (p = 0.073) for 5, 10, and 20 min of delay, respectively. Meanwhile, for MCI/AD subjects this overall bias was 0.35% [−0.12%:0.82%] (p = 0.140) for 5 min, 0.61% [−0.28%:1.5%] (p = 0.178) for 10 min, and 0.92% [−0.68%:2.5%] (p = 0.261) for 20 min of delay (Additional file 2: Table S11). The largest regional average DVR bias due to delays was −0.69% [−1.1%:0.29%] (p = 0.001) for HC subjects (VOI 6) and 1.5% [−0.6%:3.5%] (p = 0.156) for MCI/AD subjects (VOI 4), both with a 20-min delay (Additional file 2: Table S12).

**SUVR quantification**

Quantification with SUVR90 overestimated the DVR from both 2TCM and Ref Logan models (Additional file 3: Fig. S2). The level of overestimation was not constant throughout subjects and was not directly related to the regional SUVR90 value itself. Such behavior was independent of subject diagnosis; however, one AD patient had lower SUVR than 2TCM DVR in some of its target regions.

**Tracer perfusion changes**

Figure 1e, f shows the regional average bias for SUVR90 of TACs with changed perfusion relative to the SUVR90 of TAC120 (which has the fitted $K_1$ and $k_2$ values of each subject). SUVR90 of HC subjects was only slightly affected by perfusion changes with $R_1$ constant, with overall bias ranging from 1.8% [1.3%:2.3%] (p < 0.001) for $K_1$-50% to −0.92% [−1.1%:−0.76%] (p < 0.001) for $K_1$ + 50%. Meanwhile, for MCI/AD subjects the overall SUVR90 bias for perfusion changes with constant $R_1$ ranged from −15.1% [−25.1%:−5.1%] (p = 0.003) for $K_1$-50% to 4.8% [0.78%:8.8%] for $K_1$ + 50% (p = 0.019). The largest regional SUVR90 bias was 6.8% [5.2%:8.4%] (p < 0.001, VOI 2, $K_1$-50%) and −19.4% [−37.7%:−1.04%] (p = 0.038, VOI 4, $K_1$-50%) for HC and MCI/AD subjects,
respectively. More details can be found in the Additional file 2: Tables S13 and S14.

For perfusion changes with a variable $R_1$, the overall SUVR$_{90}$ bias ranged from 9.4% [5.9%:13.0%] ($p<0.001$) with $K_1$-50% to $-3.5%$ [$-4.7%$:$-2.3%$] ($p<0.001$) with $K_1$+50% for HC subjects, while for MCI/AD subjects this bias ranged from $-3.3%$ [$-11.0%$:$4.4%$] ($p=0.399$) with $K_1$-50% to $-0.15%$ [$-3.0%$:$2.7%$] ($p=0.916$) with $K_1$+50% (when compared against SUVR$_{90}$ of TAC$_{120}$). The largest regional SUVR$_{90}$ bias for HC subjects was 14.9% [9.6%:20.2%] ($p<0.001$, VOI 2, $K_1$-50%), while for MCI/AD subject it was $-8.0%$ [$-21.9%$:$5.9%$] ($p=0.260$, VOI 4, $K_1$-50%). More details can be found at the Additional file 2: Tables S15 and S16.

Non-compliance with late time static scan protocol

A delayed start of the late time static scans affected mainly the SUVR$_{90}$ of MCI/AD subjects, in contrast to HC subjects (Fig. 3). Overall, SUVR$_{90}$ of HC subjects was underestimated (when compared to the SUVR$_{90}$ of the acquisition without delays) by $-0.39%$ [$-0.55%$:$-0.23%$] ($p<0.001$), $-0.77%$ [$-1.1%$:$-0.45%$] ($p<0.001$), and $-1.5%$ [$-2.1%$:$-0.83%$] ($p<0.001$) for 5 min, 10 min, and 20 min delays, respectively. Meanwhile, the SUVR$_{90}$ of MCI/AD subjects was, in overall, overestimated by $1.6%$ [0.38%:2.9%] ($p=0.010$), $3.2%$ [0.70%:5.6%] ($p=0.012$), and $6.0%$ [1.2%:10.9%] ($p=0.015$) with 5-min, 10-min, and 20-min delays, respectively (Additional file 2: Table S17). More specifically, the largest regional SUVR$_{90}$ bias for HC subjects was $-3.5%$ [$-4.1%$:$-2.9%$] ($p<0.001$, VOI 2, delay of 20 min), while for MCI/AD subjects it was $7.9%$ [$-0.3%$:$16.1%$] ($p=0.059$, VOI 4, delay of 20 min). More details can be found at the Additional file 2: Tables S17 and S18.

Discussion

For this study, a DTW PET protocol for $[^{18}F]$MK-6240 PET imaging was considered while using a Ref Logan for DVR quantification, as well as the simulation of perfusion changes and scanning protocol non-compliance. As such, it was possible to reduce the overall acquisition time, therefore, potentially increasing patient comfort and clinical route feasibility while approximating a quantitative approach using full dynamic scanning. For the evaluation of different DTW protocols, dynamic PET data based on patient data was simulated up to 120-min post-injection and brain regions related to Braak Stages were considered. This way, realistic and clinically relevant datasets were generated for the regional assessment of a wide range of tau accumulation levels.

Presently, Ref Logan was assumed to be independent of the reference tissue clearance rate ($k_2$), which requires a late equilibrium time. To assess if the mismatch between 2TCM and Ref Logan for high binding subjects comes from the violation of this assumption, the 2TCM cerebellar $k_2$ was used as $k_2'$ on the Ref Logan model. This was done with a population-based $k_2'$ as an average of the cerebellar $k_2$ from all subjects, and with each individual's cerebellar $k_2$ as Ref Logan's $k_2'$. As there was no improvement on the agreement between the kinetic models (Additional file 1: Fig. S1), it is reasonable to trust the applicability of the Ref Logan model as independent of reference tissue clearance rate and indicates that the mismatch for high binding subjects is not a violation of this assumption.

Changes in perfusion had, in general, a significant impact on Ref Logan DVR estimations of MCI/AD subjects. It was observed that halving $K_1$ lead to a regional DVR underestimation larger than 5% for most target regions, either when $R_1$ was constant or variable (Fig. 1). Such extreme change in perfusion is not traditionally expected on longitudinal assessment of patients; however, these simulations were included to better understand general trends in quantification as function of perfusion changes and include possible extreme cases that could come from an interplay between disease progression and a possible drug effect. For less drastic perfusion changes, the average DVR bias was less than 3.5% for any target region, perfusion change (constant $R_1$ or not), and subject diagnosis (Fig. 1). Therefore, such results indicate that a Ref Logan modelling using the cerebellar cortex as reference region can be a reasonable approach for longitudinal tau assessment of MCI and AD patients, or perhaps even for subjects undergoing treatment which may affect CBF and BBB functionalities. Furthermore, the simulation with variable $R_1$ violates the assumption of reference tissue models that the ratio $K_1/k_2$ is the same for both target and reference tissues. As such, this simulation tested the robustness of the Ref Logan model and showed reliable quantification even when using a reference region that may have some PET signal (e.g. from spill-over, partial volume effects, or non-specific binding).

Regarding the introduction of a gap in the time-activity curves, it was demonstrated that a DTW protocol with a 60-min break between two 30-min dynamic acquisitions provided, on average, a bias of less than 2.5% when compared to a full dynamic scanning protocol (Fig. 2). This bias level is on the range of the expected test–retest variability [23–25] for AD studies and shorter breaks resulted in less quantification bias, which is in line with previous literature [14, 26, 27]. However, compared to shorter breaks, a 60-min break DTW protocol allows for efficient use of hospital facilities without compromising quantification accuracy since it still provides enough flexibility to schedule an interleaved clinical study while having
low bias when compared against an uninterrupted 120-min scan. Additionally, by halving the total acquisition time, this DTW protocol ($TAC_{DTW60}$) has the potential to decrease patient discomfort and, therefore, we considered this design as the DTW protocol of choice. Presently, a simple linear interpolation was performed to fill the gap in the TAC. Even though a previous study found that filling the DTW gap with more advanced techniques could improve quantification, linear interpolation still resulted in comparable results to those obtained from uninterrupted scanning [27]. Another scanning protocol option previously explored in the literature would be one uninterrupted dynamic PET scanning session of 60 min using the reference Logan plot to estimate the DVR values, as this approach provided low quantitative bias when compared to a more lengthy scanning session [5]. However, a scanning session of 60 min without a break could already be difficult to tolerate for patients suffering from significant cognitive decline. Moreover, the proposed DTW protocol is identical to other DTW protocols recommended for $[^{18}F]$Flutemetamol and $[^{18}F]$Florbetaben PET studies [14], which further facilitates its implementation as having the same protocol for different studies can simplify clinical workflow.

Next, the impact of changes in perfusion on the Ref Logan DVR quantification using the DTW 60-min break protocol was compared to the DVR results from the full dynamic scan analysis ($TAC_{120}$). Furthermore, late time SUVR$_{90}$ of TACs with perfusion changes were compared with the SUVR$_{90}$ of the unaltered acquisition (fitted $K_1$ and $k_2$ parameters). It was observed that perfusion changes lead up to a regional DVR bias of 10% or less (Fig. 1), while for SUVR$_{90}$ it was up to $-19\%$, showing that quantification of static images is more vulnerable to perfusion changes than the Ref Logan model. Ref Logan DVR from $TAC_{DTW60}$ had a smaller range on the 95% confidence interval than SUVR90 (Additional file 2: Tables S8, S10, S14 and S16), showing that it can be more reliable against perfusion changes than SUVR. Furthermore, DVR dependence on perfusion with either constant or variable $R_1$ was similar: lower perfusion (lower $K_1$ values) decreased DVR of MCI/AD subjects and increased perfusion overestimated their DVR, while HC subjects were essentially unaffected (Fig. 1c, d). SUVR$_{90}$ dependence on perfusion was different with constant $R_1$ and variable $R_1$. With constant $R_1$, SUVR$_{90}$ of MCI/AD subjects was directly related to perfusion (similar to what was observed on DVR estimates), while for HC subjects the SUVR$_{90}$ had an opposite trend: increasing with lower perfusion and decreasing when perfusion increased (Fig. 1e). With variable $R_1$, on the other hand, the SUVR$_{90}$ variability for MCI/AD subjects was dependent on target region: on NFT-poor regions the behavior was similar to HC subjects, while on NFT-rich regions (high uptake VOIs: 1, 3, 3+, and 4) SUVR$_{90}$ was essentially not affected (small effect size and $p > 0.05$) with exception of $K_1$-50% changes, which showed larger differences when compared to SUVR$_{90}$ from TAC with fitted $K_1$. Furthermore, SUVR$_{90}$ of HC subjects was increased with lower perfusion and decreased with higher perfusion, a similar trend when compared to perfusion changes with constant $R_1$. Since reliable quantification requires a method that is unaffected by $K_1$ and $k_2$ changes, a DTW approach is preferred to SUVR$_{90}$ quantification, since otherwise perfusion, plasma clearance, and BBB functionality changes can introduce a confounding factor for assessment of drug effects, follow-up studies, and disease staging, especially in diseases such as Alzheimer’s and stroke where vascular changes or changes in BBB permeability are to be expected.

Non-compliance with the scanning protocol led to an overestimation of the SUVR$_{90}$ of MCI/AD subjects with longer delays, reaching an overall average overestimation of 6.0% [1.2%:10.9%] ($p = 0.015$) for 20 min of delay (Additional file 2: Table S17). This indicates that $[^{18}F]$MK-6240 uptake is not in an equilibrium state after 140 min of uptake, which was also observed for high-binding subjects on a previous study [5] but contradicts the equilibrium found at 90 min p.i. by another group [4]. Without reaching an equilibrium, it is not possible to compare SUVR values estimated from different time windows and then deviations from the clinical protocol will lead to a bias on patient assessment. Since published studies have used different time windows for SUVR estimation, such as 60–90 min p.i. [6], 70–90 min p.i. [3, 5], 90–110 min [4, 7], and 90–120 min p.i. [5, 24], the SUVR values from these studies cannot be compared. However, SUVR at the 90–120-min window shows promising test–retest results for NFT-rich regions of AD subjects (6±2%) and could possibly be a suitable metric for cross-sectional patient assessment [24] as long as there are no deviations from the scanning protocol. That study also found that NFT-poor regions presented higher test–retest variability (14±6%). Contrary to SUVR, overall Ref Logan DVR was not impacted by scan delays (effect size <1% regardless of diagnosis and delay length; Additional file 2: Table S11) and its use is recommended over SUVR for quantification on a time window in which tracer equilibrium has not been reached. It was observed, however, that the DVR of VOI 5 and VOI 6 were less impacted than other target regions of MCI/AD subjects (Fig. 3). That is a consequence of the lower binding found in these late-stage regions (Additional file 3: Fig. S2), showing that the DVR variability with protocol non-compliance in NFT-poor regions of patients is similar to that observed on healthy brains.
A potential limitation of SUV-based quantification of $[^{18}F]$MK-6240 is the signal spill-over from the meninges into the superior section of the cerebellum, affecting the measurements of the reference region [3, 24]. Some previous studies addressed this issue by removing the dorsal cerebellum from the reference region [3, 7, 24]; however, this decreases the signal-to-noise ratio due to its reduced size and may introduce bias on the quantification. Presently, we observed possible influence of such spill-over signal when assessing protocol delays on SUVR$_{90}$ quantification, as longer delays in the protocol lowered the SUVR$_{90}$ of HC subjects, showing an increased PET signal in the reference region as the delay increases.

The present work was a pilot study exploring the feasibility of the DTW protocol for $[^{18}F]$MK-6240 studies considering inclusion of perfusion changes, and therefore, additional validation with larger cohorts is required. One of the current main limitations is the analysis of noiseless TACs, which does not completely represent a real scenario of PET data. Nevertheless, a similar study for amyloid tracers did not find strong effects of noise in their quantification from DTW simulations [15]. Furthermore, since the simulated TACs were extrapolated from real data of shorter acquisition time, there could be a bias on the late time point of the TAC. Another limitation is the small sample size, which makes it difficult to draw definitive conclusions on the best clinical protocol to be used for future $[^{18}F]$MK-6240 studies; nevertheless, subjects corresponding to different levels of specific binding were evaluated. Additionally, arterial sampling failed for the two AD subjects with highest tracer binding (S7 and S8) and, therefore, their simulated TACs were generated using a population-based input curve of the other MCI/AD subjects. Their bias was already expected to be higher than lower binding subjects [4, 5], and the population-based input curve could introduce further quantitative bias. Finally, an actual dual-time-window acquisition would require alignment between the two PET acquisitions, making the analysis more laborious and potentially introduce a small bias due to image registration misalignments [28], however, this was not an issue for previously published studies using dual-time-window protocols.

Conclusions

Reliable quantification with reference region methods for $[^{18}F]$MK-6240 can be performed from dual-time-window PET protocols with 60-min break between two 30-min dynamic acquisitions. The Reference Logan method using the cerebellar cortex as reference region should be used as it less susceptible than SUV estimates when perfusion changes or scanning protocol non-compliance were simulated. Moreover, the reduction of the overall acquisition time has the potential to improve patient comfort and clinical feasibility while making an efficient use of the PET imaging apparatus with interleaved scan protocols. Therefore, it can increase patient throughput and optimize tracer batch use without reducing quantitative accuracy.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13550-021-00790-x.

Additional file 1. Fig S1: Correlation between Reference Logan (Ref Logan) and 2 Tissue Compartment Model (2TCM) Distribution Volume Ratios (DVR), both calculated relative to the cerebellar cortex using 120 min Time Activity Curves (TACs). For the Ref Logan DVR different approaches to estimate $k_2'$ were considered.

Additional file 2. Fig S2: Comparing Standardized Uptake Value Ratios (SUVR) using a 90 to 120 min acquisition time interval post tracer injection with Reference Logan (Ref Logan) and 2 Tissue Compartment Model (2TCM) Distribution Volume Ratios (DVR). Ratios were calculated relative to the cerebellar cortex.

Additional file 3. Tables with a detailed overview of the bias for the different quantification methods induced by either perfusion changes or non-compliance with the scanning protocol. Table S1: Bias on Reference Logan DVR due to perfusion changes with constant R1, pooling target regions. Table S2: Bias on Reference Logan DVR due to perfusion changes with constant $k_1$. Table S3: Bias on Reference Logan DVR due to perfusion changes with variable $k_1$, pooling target regions. Table S4: Bias on Reference Logan DVR due to perfusion changes with variable R1. Table S5: Bias on Reference Logan DVR due to implementation of the dual-time-window protocol, pooling target regions. Table S6: Bias on Reference Logan DVR due to implementation of the dual-time-window protocol. Table S7: Bias on Reference Logan DVR from DTW TAC due to perfusion changes with constant R1, pooling target regions. Table S8: Bias on Reference Logan DVR from DTW TAC due to perfusion changes with constant $k_1$, pooling target regions. Table S9: Bias on Reference Logan DVR from DTW TAC due to perfusion changes with variable R1, pooling target regions. Table S10: Bias on Reference Logan DVR from DTW TAC due to perfusion changes with variable $k_1$. Table S11: Bias on Reference Logan DVR from...
References

1. Villemagne VL, Foden-Tavolleti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114–24.

2. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82(4):239–59.

3. Betthauzer TJ, Cody KA, Zammitt MD, Murali D, Converse AX, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60(1):93–9.

4. Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, et al. In vivo quantification of neurofibrillary tangles with [18F]MK-6240. Alzheimers Res Ther. 2018;10(1):1–14.

5. Guehl NJ, Wooten DW, Yokell DL, Moon S-H, Dhaynaut M, Katz S, et al. Evaluation of pharmacokinetic modeling strategies for in vivo quantification of tau with the radiotracer [18F]MEM-903 in human subjects. Eur J Nucl Med Mol Imaging. 2019;46(10):2099–111.

6. Lohith TG, Bernaëcle F, Vandenbergher R, Vanembulcke M, Salinas CA, Declercq R, et al. Brain imaging of Alzheimer dementia patients and elderly controls with 18F-MK-6240: a PET tracer targeting neurofibrillary tangles. J Nucl Med. 2019;60(1):107–14.

7. Pascoal TA, Theriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020. https://doi.org/10.1093/brain/awaa188/5872095.

8. Scheinin NM, Aalto S, Koikkalainen J, Lotjonen J, Karrasch M, Kemppainen N, et al. Follow-up of [11C]PiB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. 2009;73(15):1186–92.

9. Van Berckel NBM, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54(9):1570–6.

10. Lammtsera AA. Forward to the past: the case for quantitative PET imaging. J Nucl Med. 2017;58(7):1019–24.

11. Jovalekic A, Koglin N, Mueller A, Stephens AW. New protein deposition tracers in the pipeline. EJNMMI Radiopharm Chem. 2017;1(1):11.

12. Wali J, Hostetler ED, Selnick H, Zeng Z, Miller P, Benenac F, et al. Discovery of 6-(Fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]MK-6240): a positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016;59(10):4778–89.

13. Visser D, Wolters E, Verfaillie SC, Coomans EM, Timmers T, Tuncel H, et al. Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04831-w.

14. Heeman F, Yaqub M, Lopes Alves I, Heurling K, Berkhof J, Gispert JD, et al. Optimized dual-time-window protocols for quantitative [18F]fluortemocil and [18F]florbetaben PET studies. EJNMMI Res. 2019;9(1):32.

15. Heeman F, Yaqub M, Lopes Alves I, Heurling K, Bullich S, Gispert JD, et al. Simulating the effect of cerebral blood flow changes on regional quantification of [18F]fluortemocil and [18F]florbetaben studies. J Cereb Blood Flow Metab. 2021;41(3):579–589.

16. Gaser C, Dahnh R, Kurth K, Luders E. A Computational anatomy toolbox for the analysis of structural MRI data. NeuroImage. in review.

17. Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26(3):839–51.

18. D’Agostino E, Maes F, Vandermeulen D, Suetens P. Non-rigid atlas-to-image registration by minimization of class-conditional image entropy. In: Barillot C, Haynor DR, Helfer P, editors. Medical Image Computing and Computer-Assisted Intervention—MICCAI 2004. Berlin: Springer; 2004. p. 745–53. https://doi.org/10.1007/978-3-540-30135-6_91.

19. Hammers A, Allom R, Koepf MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particu-

20. Hamers A, Allom R, Koepf MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particu-

21. Zeger SL, Liang KY. Longitudinal data analysis and discrete and continu-

22. Ma Y, Mazumdar M, Mimtsoudis SG. Beyond repeated-measures analysis of variance: advanced statistical methods for the analysis of longitudinal data in anesthesia research. Reg Anesth Pain Med. 2012;37(1):99–105.

23. Golla SS, Verfaillie SC, Boellaard R, Adriaanse SM, Zwan MD, Schuit RC, et al. Quantification of [18F]florbetapir: a test–retest tracer kinetic model-

24. Kolinger et al. EJNMMI Res (2021) 11:49

Acknowledgements

We thank the staff of the Memory Clinic and of the Nuclear Medicine Department of University Hospital Leuven for their contribution in conducting the study. We sincerely thank the healthy volunteers, MCI/AD subjects, and their families for their participation in the study.

Authors’ contributions

GDK, DVG, RB, and MK were responsible for study design, image processing and quantification, data analysis, and initial manuscript draft. RB and MK managed the study. TGL, EDH, CS, and AS provided essential feedback on study design and data analysis. All authors read and approved the final manuscript.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: GDK, DVG, RB, and MK have received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie [Grant Agreement No 764458].

Availability of data and materials

The datasets generated and/ or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was conducted at the University Hospital Leuven, Belgium, and approved by the local Ethics Committee (University Hospitals Leuven/KU Leu-

Consent for publication

All authors consent for publication and all subjects enrolled in the study agreed for their data to be used for further analyses.

Competing interests

TGL, EDH, CS, and AS are or were employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Kenilworth, NJ USA, at the time of the study and may own stock and/or hold stock options in the Company.

Author details

1 Medical Imaging Center, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. 2 Translational Imaging Biomarkers, Merck & Co., Inc., 770 Summeytown Pike, Mallistop WP44D-216, West Point, PA 19486, USA. 3 Translational Pharmacology, Merck & Co., Inc, 351 N Summeytown Pike, Mallistop UG4D-48, North Wales, PA 19454, USA. 4 Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Location VU Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. 5 Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Herestraat 49 – Bus 7003, 3000 Leuven, Belgium.

Received: 23 November 2020 Accepted: 17 May 2021

Published online: 27 May 2021
24. Salinas C, Lohith TG, Purohit A, Struyk A, Sur C, Bennacef I, et al. Test–retest characteristic of [18F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer’s disease. J Cereb Blood Flow Metab. 2019. https://doi.org/10.1177/0271678X19887781.

25. Tolboom N, Yaqub M, Boellaard R, Luurtsema G, Windhorst AD, Scheltens P, et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2009;36(10):1629–38.

26. Lopes Alves I, Willemsen AT, Dierckx RA, da Silva AMM, Koole M. Dual time-point imaging for post-dose binding potential estimation applied to a [11C]raclopride PET dose occupancy study. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2017;37(3):866–76.

27. Bullich S, Barthel H, Koglin N, Becker GA, Santi SD, Jovalekic A, et al. Validation of noninvasive tracer kinetic analysis of 18F-florbetaben PET using a dual–time-window acquisition protocol. J Nucl Med. 2018;59(7):1104–10.

28. Nørgaard M, Ganz M, Svarer C, Feng L, Ichise M, Lanzenberger R, et al. Cerebral serotonin transporter measurements with [11C]DASB: a review on acquisition and preprocessing across 21 PET centres. J Cereb Blood Flow Metab. 2019;39(2):210–22.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.